Log In
BCIQ
Print this Print this
 

fasitibant (MEN16132)

  Manage Alerts
Collapse Summary General Information
Company Menarini Group
DescriptionBradykinin B2 receptor (BDKRB2; B2R) antagonist
Molecular Target Bradykinin B2 receptor (BDKRB2) (B2R)
Mechanism of ActionBradykinin receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationOsteoarthritis
Indication DetailsTreat osteoarthritis (OA) of the knee
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today